Novo Nordisk Stock Climbs on Strong Oral Weight Loss Drug Sales

Key Stats for Novo Nordisk Stock

• 1- Year Price Change for Novo Nordisk stock: -25%
• $NVO Share Price as of Jan. 16: $62.33
• 52-Week High: $93.80
• $NVO Share Price Target: $56

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

What Happened?

Novo Nordisk (NVO) stock jumped over 9% after the company’s new oral Wegovy pill posted strong early sales numbers.

• In just the first four days after launch, retail pharmacies filled about 3,071 prescriptions for the once-daily weight-loss pill.
• That number doesn’t even include prescriptions from Novo Nordisk’s own NovoCare Pharmacy, so actual demand is likely higher.
• The oral pill brings a new option for the more than 100 million Americans living with obesity. Up until now, patients had to use weekly injections.
• The pill delivers the same semaglutide medication as the injectable version but in a daily tablet form. In clinical trials, patients who stayed on treatment lost an average of 17% of their body weight.

Ed Cinca, senior vice president at Novo Nordisk, put it this way:

“We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill.”

The company made the pill available through multiple channels, including CVS, Costco, and telehealth providers like Ro and Weight Watchers.

Self-pay patients can start at $149 per month for the starter dose, while insured patients may pay as little as $25 monthly.

See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>

What the Market Is Telling Us About Novo Nordisk Stock

Investors are betting that oral weight-loss drugs will capture a big share of the growing obesity treatment market.

Industry analysts project that pills could make up more than a third of all GLP-1 prescriptions by 2030. That’s a huge shift from today’s market, which is dominated by weekly injections.

Novo Nordisk stock got a boost because the early prescription data signals real patient demand for a non-injectable option. The company is first to market with an FDA-approved oral GLP-1 pill for obesity, giving it an early advantage over competitors like Eli Lilly, whose oral candidate is still under review.

But competition is heating up fast. Eli Lilly’s forglipron could hit the market soon, and both companies are racing to grab market share. Novo Nordisk stock will likely stay sensitive to news about competitor progress and ongoing prescription trends in the coming months.

For now, the strong launch gives Novo Nordisk a head start in what could become a massive new segment of the weight loss market.

Estimate a company’s fair value instantly (Free with TIKR) >>>

How Much Upside Does Novo Nordisk Stock Have From Here?

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2.  Operating Margins
3.  Exit P/E Multiple

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>

Looking for New Opportunities?

• See what stocks billionaire investors are buying so you can follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!